UK markets closed

Enliven Therapeutics, Inc. (ELVN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
23.37-0.08 (-0.34%)
At close: 04:00PM EDT
23.30 -0.07 (-0.30%)
After hours: 05:54PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-79,598
-71,584
-37,662
-24,740
-18,966
Depreciation & amortisation
309
297
215
115
45
Stock-based compensation
15,167
12,914
3,191
1,924
130
Change in working capital
5,215
1,401
438
3,567
583
Accounts payable
-587
-2,250
411
1,734
291
Other working capital
-63,924
-61,418
-32,689
-19,325
-8,990
Other non-cash items
-
306
-
-
9,679
Net cash provided by operating activities
-63,786
-61,269
-32,077
-19,134
-8,529
Cash flows from investing activities
Investments in property, plant and equipment
-138
-149
-612
-191
-461
Purchases of investments
-325,041
-268,263
0
-
-
Sales/maturities of investments
158,913
120,000
0
-
-
Net cash used for investing activities
-166,266
-148,412
-612
-191
-461
Cash flows from financing activities
Common stock issued
-
-
-
690
140
Common stock repurchased
-
-
-
-226
-
Other financing activities
-
233,887
-2,390
-1,480
-
Net cash used provided by (used for) financing activities
87,115
234,286
-1,799
-1,016
130,513
Net change in cash
-142,937
24,605
-34,488
-20,341
121,523
Cash at beginning of period
292,156
75,590
110,078
130,419
8,896
Cash at end of period
149,219
100,195
75,590
110,078
130,419
Free cash flow
Operating cash flow
-63,786
-61,269
-32,077
-19,134
-8,529
Capital expenditure
-138
-149
-612
-191
-461
Free cash flow
-63,924
-61,418
-32,689
-19,325
-8,990